| (Values in U.S. Thousands) | Sep, 2020 | Jun, 2020 | Mar, 2020 | Dec, 2019 | Sep, 2019 |
| Sales | 0 | 0 | 120 | 2,070 | 0 |
| Sales Growth | unch | -100.00% | -94.20% | unch | unch |
| Net Income | -4,640 | -6,390 | -5,780 | -5,290 | -5,940 |
| Net Income Growth | +27.39% | -10.55% | -9.26% | +10.94% | +4.81% |
Sunesis Pharmaceutic (SNSS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies.